Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Laura J Rojas *Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0003-4410-1658
Travis B Nielsen *Division of Infectious Diseases, Keck School of Medicine of the University of Southern California (USC), Los Angeles, California, USA.ORCID 0000-0003-3366-7912
Paul PantapalangkoorDepartment of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California (USC), Los Angeles, California, USA.
Magdalena A TaracilaLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Maria L IntrovigneDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID 0000-0002-7670-216X
Rajnikant SharmaDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-0891-7548
Shekhar YeshwanteDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0009-0003-5968-1007
Maria F MojicaDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-1380-9824
Krisztina M Papp-WallaceJMI Laboratories/Element-Iowa City, North Liberty, Iowa, USA.ORCID 0000-0002-9976-7898
Andrea M HujerLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Fabio PratiDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID 0000-0002-0650-9540
Emilia CaselliDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID 0000-0002-7248-9453
Brad SpellbergDivision of Infectious Diseases, Keck School of Medicine of the University of Southern California (USC), Los Angeles, California, USA.
Philip N RatherDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0001-9674-6250
Gauri G RaoDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-8704-7770
Robert A BonomoDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6M
BLRD VA I01 BX000447BLRD VA I01 BX001725BLRD VA I01 BX001974BLRD VA IK6 BX004470HHS | National Institutes of Health (NIH) R01AI072219HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI072219Ministry of University and Research of Italy 2022WBPFSCNIAID NIH HHS R01 AI072219U.S. Department of Veterans Affairs (VA) 1I01BX001974U.S. Department of Veterans Affairs (VA) I01BX001725, IK6BX00447
6 · The paper itself
Abstract
Foremost in the design of new β-lactamase inhibitors (BLIs) are the boronic acid transition state inhibitors (BATSIs). Two highly potent BATSIs being developed are S02030 and MB076 strategically designed to be active against cephalosporinases and carbapenemases, especially KPC. When combined with cefepime, S02030 and MB076 demonstrated potent antimicrobial activity against laboratory and clinical strains of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Restoring cefepime activity against multidrug-resistant KPC-producing · full record | OpenQuestion